Published in Infect Immun on March 01, 1999
Layer-by-layer-assembled multilayer films for transcutaneous drug and vaccine delivery. ACS Nano (2009) 1.75
Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest (2004) 1.58
Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun (2000) 1.48
Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun (2002) 1.34
Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun (2004) 1.30
Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect Immun (2002) 1.20
Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J Virol (2001) 1.19
Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect Immun (2000) 1.09
Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infect Immun (2007) 1.06
Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice. Clin Vaccine Immunol (2012) 1.02
Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge. Immunology (2001) 1.00
Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J Virol (2002) 1.00
Transcutaneous immunization with toxin-coregulated pilin A induces protective immunity against Vibrio cholerae O1 El Tor challenge in mice. Infect Immun (2006) 0.99
Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells. Immunology (2002) 0.97
Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice. J Virol (2004) 0.94
Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J Virol (2001) 0.91
Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge. PLoS One (2010) 0.91
Protection against Shiga toxin-producing Escherichia coli infection by transcutaneous immunization with Shiga toxin subunit B. Clin Vaccine Immunol (2007) 0.90
Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity. Infect Immun (2006) 0.89
The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma interferon after coapplication onto bare skin. Infect Immun (2002) 0.89
Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch. Influenza Other Respir Viruses (2008) 0.88
Topical vaccination: the skin as a unique portal to adaptive immune responses. Semin Immunopathol (2007) 0.86
Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun. Clin Vaccine Immunol (2011) 0.83
New vaccine development. BMJ (2002) 0.83
Cholera toxin B: one subunit with many pharmaceutical applications. Toxins (Basel) (2015) 0.83
Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice. Vaccine (2009) 0.82
Mucosal vaccine delivery: Current state and a pediatric perspective. J Control Release (2016) 0.80
Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines. J Neuroimmunol (2014) 0.77
Transcutaneous immunization system using a hydrotropic formulation induces a potent antigen-specific antibody response. PLoS One (2012) 0.76
The catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responses. Hum Vaccin Immunother (2015) 0.75
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev (1983) 7.16
Interaction of Vibrio cholerae enterotoxin with cell membranes. Biochemistry (1973) 4.84
A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned. Lancet (1996) 4.30
Enterotoxicity of bacteria-free culture-filtrate of Vibrio cholerae. Nature (1959) 3.60
Properties of homogeneous heat-labile enterotoxin from Escherichia coli. Infect Immun (1980) 3.36
Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun (1995) 3.22
Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun (1982) 2.61
Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis (1988) 2.57
THE PROPHYLACTIC DOSE OF HOMOLOGOUS TETANUS ANTITOXIN. N Engl J Med (1964) 2.55
Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J Immunol (1984) 2.51
The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem (1992) 2.40
Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis (1998) 2.26
Protection against experimental cholera by antitoxin. J Infect Dis (1972) 2.21
Mechanisms of disease and immunity in cholera: a review. J Infect Dis (1977) 2.17
Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med (1998) 1.98
Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli. Infect Immun (1987) 1.97
Antitoxic immunity in experimental cholera: protection, and serum and local antibody responses in rabbits after enteral and parenteral immunization. Infect Immun (1975) 1.82
The family of bacterial ADP-ribosylating exotoxins. Clin Microbiol Rev (1995) 1.73
Skin immunization made possible by cholera toxin. Nature (1998) 1.55
The mechanism of cholera toxin adjuvanticity. Res Immunol (1998) 1.51
Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit of Escherichia coli heat-labile enterotoxin. Infect Immun (1991) 1.42
Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol (1998) 1.41
The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit Rev Immunol (1995) 1.23
An oral B subunit: whole cell vaccine against cholera. Vaccine (1992) 1.20
Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines. Pediatr Infect Dis J (1995) 1.15
Intradermal hepatitis B virus vaccine: immunogenicity and side-effects in adults. Lancet (1984) 1.10
Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB. Vaccine (1989) 1.05
Effect of neutralization of gastric acid on immune responses to an oral B subunit, killed whole-cell cholera vaccine. J Infect Dis (1986) 1.00
Cadherins and Langerhans cell immunobiology. Clin Exp Immunol (1997) 0.95
Reducing the risk of unsafe injections in immunization programmes: financial and operational implications of various injection technologies. Bull World Health Organ (1995) 0.93
Trials of intradermal hepatitis B vaccines in Gambian children. Ann Trop Paediatr (1987) 0.90
Risk of virus transmission by jet injection. Lancet (1988) 0.83
Hepatitis B associated with jet gun injection--California. MMWR Morb Mortal Wkly Rep (1986) 0.82
Virus transmission by subcutaneous jet injection. J Med Microbiol (1985) 0.77
In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. J Exp Med (1997) 6.53
Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med (1998) 2.80
Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med (2000) 1.98
Interaction of Sindbis virus with liposomal model membranes. J Virol (1975) 1.85
Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc Natl Acad Sci U S A (1978) 1.82
Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum Gene Ther (1998) 1.76
Complement-dependent damage to liposomes prepared from pure lipids and Forssman hapten. Biochemistry (1969) 1.75
A role for CD4+ NK1.1+ T lymphocytes as major histocompatibility complex class II independent helper cells in the generation of CD8+ effector function against intracellular infection. J Exp Med (1996) 1.70
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol (2003) 1.63
Perforin-mediated cytolysis plays a limited role in host resistance to Toxoplasma gondii. J Immunol (1997) 1.60
Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci U S A (1999) 1.59
Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions. Immunity (1997) 1.56
Skin immunization made possible by cholera toxin. Nature (1998) 1.55
Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun (2000) 1.48
Decreased resistance of TNF receptor p55- and p75-deficient mice to chronic toxoplasmosis despite normal activation of inducible nitric oxide synthase in vivo. J Immunol (1998) 1.43
Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol (1998) 1.41
Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci U S A (1992) 1.37
A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J Virol (1995) 1.33
Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst (1998) 1.32
Production of antibodies against phosphocholine, phosphatidylcholine, sphingomyelin, and lipid A by injection of liposomes containing lipid A. J Immunol (1979) 1.30
Antibodies to cholesterol. Proc Natl Acad Sci U S A (1988) 1.25
Cytotoxic T lymphocytes to Ebola Zaire virus are induced in mice by immunization with liposomes containing lipid A. Vaccine (1999) 1.25
Analysis of granuloma formation in double cytokine-deficient mice reveals a central role for IL-10 in polarizing both T helper cell 1- and T helper cell 2-type cytokine responses in vivo. J Immunol (1997) 1.23
HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J Immunol (1998) 1.22
Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother (1986) 1.22
Delivery of liposome-encapsulated drugs to macrophages. Pharmacol Ther (1983) 1.20
Improved therapy of experimental leishmaniasis by use of a liposome-encapsulated antimonial drug. Life Sci (1978) 1.19
Antibodies to liposomes, phospholipids and phosphate esters. Chem Phys Lipids (1986) 1.16
Lipid A from endotoxin: antigenic activities of purified fractions in liposomes. J Immunol (1979) 1.16
Binding of diphtheria toxin to phospholipids in liposomes. Proc Natl Acad Sci U S A (1980) 1.16
Interactions of lectins with glycolipids in liposomes. Biochem Biophys Res Commun (1977) 1.12
Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am J Physiol Heart Circ Physiol (2000) 1.12
Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J Liposome Res (2003) 1.11
Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes. J Immunol (1977) 1.09
Activation of human complement by liposomes: a model for membrane activation of the alternative pathway. J Immunol (1979) 1.08
Interaction of C-reactive protein with liposomes. III. Membrane requirements for binding. J Immunol (1981) 1.06
Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J Infect Dis (1996) 1.05
Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice. Antimicrob Agents Chemother (1985) 1.04
Comparative properties of four galactosyl lipids as antigens in liposomes. Immunochemistry (1974) 1.04
Liposomes, lipid A, and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen. Infect Immun (1988) 1.03
Choleragen-mediated release of trapped glucose from liposomes containing ganglioside GM1. Proc Natl Acad Sci U S A (1976) 1.01
Antibody binding and complement fixation by a liposomal model membrane. Biochemistry (1969) 1.01
Adjuvant effects of liposomes containing lipid A: enhancement of liposomal antigen presentation and recruitment of macrophages. Infect Immun (1992) 1.01
Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigen. Vaccine (1995) 1.00
Transcutaneous immunization of domestic animals: opportunities and challenges. Adv Drug Deliv Rev (2000) 1.00
Transcutaneous immunization: T cell responses and boosting of existing immunity. Vaccine (2001) 0.99
Influence of membrane composition on the interaction of a human monoclonal "anti-Forssman" immunoglobulin with liposomes. Biochemistry (1974) 0.99
Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil. Adv Drug Deliv Rev (2000) 0.99
Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J Immunol (1995) 0.99
Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen. Infect Immun (1998) 0.98
Cholesterol-dependent tetanolysin damage to liposomes. Biochim Biophys Acta (1979) 0.98
Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen. Vaccine (1986) 0.97
Principles of transcutaneous immunization using cholera toxin as an adjuvant. Vaccine (1999) 0.96
Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol (2001) 0.96
Liposomes as vehicles for vaccines. Prog Clin Biol Res (1980) 0.96
Advances in vaccine delivery: transcutaneous immunisation. Expert Opin Investig Drugs (1999) 0.95
Choleragen (cholera toxin): a bacterial lectin. Proc Natl Acad Sci U S A (1979) 0.94
Interactions of lipid a and liposome-associated lipid A with Limulus polyphemus amoebocytes. Infect Immun (1983) 0.94
Heterogeneity of lipid A. Rev Infect Dis (1984) 0.93
Liposomes in leishmaniasis: therapeutic effects of antimonial drugs, 8-aminoquinolines, and tetracycline. Life Sci (1980) 0.92
The role of dendritic cells in the initiation of host resistance to Toxoplasma gondii. Adv Exp Med Biol (1998) 0.92
Liposomes as carriers for vaccines. Immunomethods (1994) 0.91
Immune reactivities of antibodies against glycolipids--I. Properties of anti-galactocerebroside antibodies purified by a novel technique of affinity binding to liposomes. Immunochemistry (1977) 0.91
Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery. J Pharm Sci (1999) 0.90
Phagocytosis of liposomes by macrophages: intracellular fate of liposomal malaria antigen. Biochim Biophys Acta (1991) 0.90
Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog. Am J Vet Res (1984) 0.90
Suppression of cytotoxicity of diphtheria toxin by monoclonal antibodies against phosphatidylinositol phosphate. Biophys J (1982) 0.90
Heterogeneity of lipid A: comparison of lipid A types from different gram-negative bacteria. J Bacteriol (1984) 0.90
Natural antibodies against phospholipids and liposomes in humans. Biochem Soc Trans (1984) 0.90
Liposomal subunit vaccines: effects of lipid A and aluminum hydroxide on immunogenicity. J Pharm Sci (1996) 0.90
Interactions of C-reactive protein and complement with liposomes. II. Influence of membrane composition. J Immunol (1979) 0.90
Lipid A fractions analyzed by a technique involving thin-layer chromatography and enzyme-linked immunosorbent assay. Eur J Biochem (1984) 0.89
Phosphate-binding specificities of monoclonal antibodies against phosphoinositides in liposomes. Mol Immunol (1984) 0.89
Immunologic approaches to the treatment of prostate cancer. Semin Oncol (1999) 0.89
Influence of glycolipids on immune reactions of phospholipid antigens in liposomes. Biochim Biophys Acta (1985) 0.88
Liposomal chemotherapy in visceral leishmaniasis: an ultrastructural study of an intracellular pathway. Z Parasitenkd (1983) 0.88
Partially protective vaccination permits the development of latency in a normally virulent strain of Toxoplasma gondii. Infect Immun (1998) 0.87
Mitogenic activities of lipid A and liposome-associated lipid A: effects of epitope density. Rev Infect Dis (1984) 0.87
Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A. Vaccine (1989) 0.87
Enhancement by lipid A of mucosal immunogenicity of liposome-associated cholera toxin. Rev Infect Dis (1984) 0.87
Effects of negatively charged lipids on phagocytosis of liposomes opsonized by complement. Biochim Biophys Acta (1983) 0.87
Studies on the topography of the catalytic site of acetylcholinesterase using polyclonal and monoclonal antibodies. J Neurochem (1990) 0.87
Sporozoite-induced malaria: therapeutic effects of glycolipids in liposomes. Science (1979) 0.87
Effects of lipid A and liposomes containing lipid A on platelet and fibrinogen production in rabbits. Blood (1980) 0.86
Effect of the A and B protomers of choleragen on release of trapped glucose from liposomes containing or lacking ganglioside GM1. J Biol Chem (1977) 0.86
Induction and detection of antibodies to squalene. J Immunol Methods (2000) 0.85
The preparation and properties of liposomes in the LA and LAC states. Immunochemistry (1971) 0.85
Immune damage to liposomes containing lipids from Schistosoma mansoni worms. Proc Soc Exp Biol Med (1974) 0.85
Light-induced leakage of spin label marker from liposomes in the presence of phototoxic phenothiazines. Photochem Photobiol (1976) 0.85